adr_usa_0503|ASLN|0|total_current_assets|cash_on_hand|inventories_net|net_ppe|goodwill_and_intangible|liabilities|total_current_liabilities|total_long_term_liab|total_deposits|book_value_of_equity|retained_earnings|treasury_stock|ev_revenues|ev_earnings|ev_free_cash_flow|ev_assets|ps_ratio|pe_ratio|price_to_book_value|peg_ratio|debt_equity_ratio|dividend_yield|shareholder_yield_ttm|percent_of_shares_outstanding|receivables|payables|capital_stock|return_on_invested_capital|quality_ratio_fractile|momentum_fractile|market_beta_12_month|sustainable_growth_rate|institutional_investor_ownership_percentage|average_shares_outs_diluted|total_employee_number|eps|shares_outstanding|repurchase_of_capital_stock|ordinary_shares_number|payout_ratio|quick_ratio|normalized_eps|stock_buyback|effective_tax_rate|return_on_equity|net_income_ttm|revenues_ttm|dividend_per_share|revenues|gross_profit|sga_expense|pre_tax_income|net_income|interest_income|price|total_return_price|enterprise_value|average_volume_30|one_year_return|price_next_month|price_second_month
adr_usa_0503|ASLN|1|ASLAN Pharmaceuticals Ltd Total Current Assets (Quarterly) (USD)|ASLAN Pharmaceuticals Ltd Cash and Short Term Investments (Quarterly) (USD)|ASLAN Pharmaceuticals Ltd Inventories (Quarterly) (USD)|ASLAN Pharmaceuticals Ltd Net PP&E (Quarterly) (USD)|ASLAN Pharmaceuticals Ltd Goodwill and Intangibles (Quarterly) (USD)|ASLAN Pharmaceuticals Ltd Total Liabilities (Quarterly) (USD)|ASLAN Pharmaceuticals Ltd Total Current Liabilities (Quarterly) (USD)|ASLAN Pharmaceuticals Ltd Total Long Term Liabilities (Quarterly) (USD)|ASLAN Pharmaceuticals Ltd Total Deposits (Quarterly) (USD)|ASLAN Pharmaceuticals Ltd Book Value (Quarterly) (USD)|ASLAN Pharmaceuticals Ltd Retained Earnings (Quarterly) (USD)|ASLAN Pharmaceuticals Ltd Treasury Stock (Quarterly) (USD)|ASLAN Pharmaceuticals Ltd EV to Revenues|ASLAN Pharmaceuticals Ltd EV to Earnings|ASLAN Pharmaceuticals Ltd EV to Free Cash Flow|ASLAN Pharmaceuticals Ltd EV to Assets (Quarterly)|ASLAN Pharmaceuticals Ltd PS Ratio|ASLAN Pharmaceuticals Ltd PE Ratio|ASLAN Pharmaceuticals Ltd Price to Book Value|ASLAN Pharmaceuticals Ltd PEG Ratio|ASLAN Pharmaceuticals Ltd Debt to Equity Ratio|ASLAN Pharmaceuticals Ltd Dividend Yield|ASLAN Pharmaceuticals Ltd Shareholder Yield (TTM)|ASLAN Pharmaceuticals Ltd Percent of Shares Outstanding Short|ASLAN Pharmaceuticals Ltd Total Receivables (Quarterly) (USD)|ASLAN Pharmaceuticals Ltd Total Payables (Quarterly) (USD)|ASLAN Pharmaceuticals Ltd Total Capital Stock (Quarterly) (USD)|ASLAN Pharmaceuticals Ltd Return on Invested Capital|ASLAN Pharmaceuticals Ltd Quality Ratio Score|ASLAN Pharmaceuticals Ltd Momentum Score|ASLAN Pharmaceuticals Ltd Beta (1Y)|ASLAN Pharmaceuticals Ltd Sustainable Growth Rate (TTM)|ASLAN Pharmaceuticals Ltd Institutional Investor Ownership Percentage|ASLAN Pharmaceuticals Ltd Average Diluted Shares Outstanding (Quarterly)|ASLAN Pharmaceuticals Ltd Total Employees (Annual)|ASLAN Pharmaceuticals Ltd EPS Diluted (Quarterly) (USD)|ASLAN Pharmaceuticals Ltd Shares Outstanding|ASLAN Pharmaceuticals Ltd Repurchase of Capital Stock (Quarterly) (USD)|ASLAN Pharmaceuticals Ltd Ordinary Shares Number (Quarterly)|ASLAN Pharmaceuticals Ltd Payout Ratio|ASLAN Pharmaceuticals Ltd Quick Ratio (Quarterly)|ASLAN Pharmaceuticals Ltd Normalized Diluted EPS (Quarterly) (USD)|ASLAN Pharmaceuticals Ltd Stock Buybacks (Quarterly) (USD)|ASLAN Pharmaceuticals Ltd Effective Tax Rate (TTM)|ASLAN Pharmaceuticals Ltd Return on Equity|ASLAN Pharmaceuticals Ltd Net Income (TTM) (USD)|ASLAN Pharmaceuticals Ltd Revenue (TTM) (USD)|ASLAN Pharmaceuticals Ltd Dividend Per Share (Quarterly) (USD)|ASLAN Pharmaceuticals Ltd Revenue (Quarterly) (USD)|ASLAN Pharmaceuticals Ltd Gross Profit (Quarterly) (USD)|ASLAN Pharmaceuticals Ltd SG&A Expense (Quarterly) (USD)|ASLAN Pharmaceuticals Ltd Pre-Tax Income (Quarterly) (USD)|ASLAN Pharmaceuticals Ltd Net Income (Quarterly) (USD)|ASLAN Pharmaceuticals Ltd Net Interest Income (Quarterly) (USD)|ASLAN Pharmaceuticals Ltd Price (USD)|ASLAN Pharmaceuticals Ltd Total Return Price (USD)|ASLAN Pharmaceuticals Ltd Enterprise Value (USD)|ASLAN Pharmaceuticals Ltd 30-Day Average Daily Volume|ASLAN Pharmaceuticals Ltd 1 Year Price Returns (Daily)||
adr_usa_0503|ASLN|2|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|percent_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|percent_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_beta|percent_USD_metric|percent_USD_metric|mil_figure_USD_metric|figure_whole_USD_metric|figure_money_USD_per_share_metric|mil_figure_USD_metric|mil_figure_money_USD_metric|mil_figure_USD_metric|percent_USD_metric|figure_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_price|figure_money_USD_price|mil_figure_money_USD_metric|figure_USD_metric|percent_USD_metric||
adr_usa_0503|ASLN|4|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|quarterly|quarterly|daily|daily|quarterly|daily|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|daily|daily|daily|daily||
adr_usa_0503|ASLN|5|98.2307692308|98.2307692308||98.2307692308|98.2307692308|98.2307692308|98.2307692308|98.2307692308||98.2307692308|98.2307692308|||91.375|1.44249201278|92|||1.44391408115|1.43373493976|91.25|1.44943820225|91.3333333333|15.2456140351|98.8333333333|98.2307692308|98.2307692308|91.2857142857||30.5333333333|30.5|91.5|30.5|91.2941176471|547.75|91.2941176471|56.25||98.2307692308|91.25|91.25|91.2941176471|91.4|91.4|91.5|91.2142857143|||91.2727272727|91.375|91.2941176471|91.2941176471|91.2941176471|91.2941176471|1.44943820225|1.44943820225|1.44249201278|1.44949494949|1.44086021505||
adr_usa_0503|ASLN|6|13|13||13|13|13|13|13||13|13|||8|626|2|||419|166|8|623|3|57|12|13|13|7||15|16|6|14|17|4|17|20||13|8|8|17|10|5|6|14|||11|8|17|17|17|17|623|623|626|594|372||
adr_usa_0503|ASLN|7|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|daily|quarterly|daily|daily|daily|daily|quarterly|daily|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|quarterly|monthly|quarterly|yearly|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|market_daily|market_daily|daily|market_daily|market_daily||
adr_usa_0503|ASLN|201312|||||||||||||||||||||||||||||||||||10||||||||||||||||||||||||||
adr_usa_0503|ASLN|201412|||||||||||||||||||||||||||||||||||19||||||||||||||||||||||||||
adr_usa_0503|ASLN|201512|||||||||||||||||||||||||||||||||||25||||||||||||||||||||||||||
adr_usa_0503|ASLN|201603||||||||||||||||||||||||||||||||||18.5153||-0.2143||||||-0.2143|||||||||1.4963|-3.9685|-3.9685|-0.1645|||||||
adr_usa_0503|ASLN|201606||||||||||||||||||||||||||||||||||19.3216||-0.1732||||||-0.1818|-8.8518||||||0.2539||1.2206|-3.3456|-3.3456|-0.1492|||||||
adr_usa_0503|ASLN|201609||||||||||||||||||||||||||||||||||23.1218||0.2277||||||0.2327|-14.2562||||||10.3238||1.9312|5.2638|5.2638|-0.0648|||||||
adr_usa_0503|ASLN|201612|52.9351|51.5563||0.3831|0.084|12.0968|3.7903|8.3065||41.4297|-48.224||||||||||0.2005||||1.2895|3.7903|35.6266|||||||26.0152||-0.2603|||130.1289||13.9425|-0.2801|0.8842|||-8.8209|||0.9617||2.2234|-6.7706|-6.7706|-0.0965|||||||
adr_usa_0503|ASLN|201703|45.987|45.8305||0.3619|0.0816|12.9474|4.2249|8.7225||33.6694|-59.8947||||||||||0.2591|||||4.2249|38.1367|||||||23.127||-0.3577|||130.1289||10.8477|-0.3577||||-13.1255|||||2.0183|-8.2731|-8.2731|-0.1027|||||||
adr_usa_0503|ASLN|201706|69.8183|69.7515||0.5306|0.079|12.8169|3.858|8.9589||57.7876|-68.9835||||||||||0.155|||||3.858|42.8254|-35.8352||||-42.8433||24.303||-0.3785|26.0258||130.1289||18.0795|-0.3785|-32.7947||-42.8433|-18.9777|||||1.917|-9.1978|-9.1978|-0.1029|||||||
adr_usa_0503|ASLN|201709|60.6525|60.5768||0.4892|0.0852|11.6074|2.383|9.2244||49.7828|-76.8409||||||||||0.1841|||||2.383|42.7864|-59.061||||-70.4262||26.0415||-0.3041|26.0258||130.1289||25.4203|-0.3041|0.0299||-70.4262|-32.1618|||||2.2278|-7.9203|-7.9203|0.0672|||||||
adr_usa_0503|ASLN|201712|50.6452|50.5732||0.4436|0.0841|15.8203|5.9788|9.8415||35.5134|-90.2833||||||||||0.2726|||||5.9788|41.514|-75.8952||||-91.4896||26.0832||-0.5643|26.0258||130.1289||8.4587|-0.5643|-0.2962||-91.4896|-39.923|||||2.6951|-14.5318|-14.5318|-0.0203|||||||
adr_usa_0503|ASLN|201803|28.6391|28.5556||0.4141|23.1019|25.3599|14.9374|10.4224||26.9564|-104.4428||||-3.8908||||7.9749|-0.0288|0.3705|||0.0578||14.9374|44.8684|-80.8092||||-99.2601||26.0152||-0.3379|26.0258||130.1289||1.9117|-0.3379|||-99.2601|-40.4405|||||3.2978|-8.7906|-8.7906|-0.1129|8.26|8.26|196.4056||||
adr_usa_0503|ASLN|201806|44.9464|44.7493||0.3682|22.9796|15.8714|5.7162|10.1552||52.6137|-109.7874|||-5.911|-4.1197|3.6497|||4.8087|-0.0496|0.1838||-14.5619|0.0182||5.7162|52.3301|-78.2741||||-94.9591||29.5862||-0.35|32.0258||160.129||7.8285|-0.35|-41.0496||-94.9591|-42.286|||||3.0641|-11.0336|-11.0434|-0.0399|8.9|8.9|249.9518|105078.2||7.9|8.0999
adr_usa_0503|ASLN|201809|34.9282|34.7897||0.3364|23.0751|16.9381|6.7252|10.2129||41.7659|-121.5055|||-5.0619|-3.6547|3.9308|||4.0363|-0.1418|0.2344||-16.6728|0.0026||6.7252|52.6065|-89.4127||||-110.3087||32.0947||-0.3496|32.0498||160.2489||5.173|-0.3496|-1.1304||-110.3087|-45.5867|||||2.7559|-11.2162|-11.2209|-0.004|7.98|7.98|230.7558|3190.5333||5.26|5.09
adr_usa_0503|ASLN|201812|29.0925|28.9089||0.2884|23.0806|22.2628|7.9984|14.2644||30.618|-132.4689|||-2.3776|-1.6058|1.8995|||3.7683|-0.0838|0.4564||-37.3917|0.0047||7.948|51.6272|-87.8058||||-112.6776||32.0729|56|-0.35|32.0498||160.2489||3.6143|-0.3511|||-112.6776|-42.2467|||||1.9007|-11.1918|-11.1918|-0.1299|3.6|3.6|100.4452|19969.3333||3.41|3.49
adr_usa_0503|ASLN|201903||||||||||||||-3.2422|-1.9592||||4.0091||||-29.2705|0.0038||||-77.3894|||2.1226|||32.0498||-0.15|32.0498|||||-0.15||-0.046||-37.8001|||3|2.9|2.2564|-4.3411|-4.344|-0.1307|4.2899|4.2899|122.5563|23630.8667|-64.77|3.83|2.91
adr_usa_0503|ASLN|201906|15.1947|15.0501||0.9611|23.0782|21.2054|5.9763|15.2291||18.4197|-144.7439|||-2.5825|-1.3342||||3.2136|||||0.2311||5.737|51.6272|||2|2.1093||8.6965|32.0498||-0.25|32.0498||160.2489|||-0.25||-1.4024||-34.6878|||||1.8854|-7.4589|-7.931|-0.127|3.07|3.07|83.4588|23337.9667|-60.5398|3.2|1.66
adr_usa_0503|ASLN|201909|8.1366|7.9935||0.8506|23.0772|19.1973|4.3224|14.8749||13.1913|-149.929|||-1.63|-0.985||||4.2032|||||0.1187||3.8206|51.6272|||1|2.4645||8.6382|32.0498||-0.15|32.0498||160.2489|||-0.1565||-1.3989||-28.652|||||1.1117|-5.2649|-5.1852|-0.2064|1.73|1.73|61.6139|30268.3333|-78.3208|1.63|3.82
adr_usa_0503|ASLN|201912|22.272|22.203||0.7662|0.0028|23.9528|5.3832|18.5695||-1.6774|-179.4848|||-1.9477|-1.177||||5.8464|||||2.8318||4.7257|61.3668|||3|3.3078||10.9814|33.7647|23|-0.9|37.991||189.955|||-0.3257||-0.8745||-47.0655||||0.0177|3.2582|-29.5927|-29.6054|-0.2869|2.03|2.03|73.6243|3021173.8333|-43.6111|2|1.8
adr_usa_0503|ASLN|202003|17.0797|16.8943||0.6909|0.0019|21.9237|3.8208|18.1029||-4.7591|-182.5315|||-1.0592|-0.64|||||||||0.0518||3.5527|61.3668|||2|3.2574||10.7088|37.991||-0.1|||189.955|||-0.1||-0.8893||-45.7682|||||0.9975|-3.2338|-3.0467|-0.3389|1.02|1.02|40.0366|176597.5333|-76.2232|1.6826|1.76
adr_usa_0503|ASLN|202006|14.1226|13.8274||0.6172|0.0009|22.9648|4.3692|18.5956||-8.7576|-186.4907|||-2.1333|-1.2892|||||||||0.0738||3.5309|61.3668|||3|4.2558||9.1838|37.991||-0.1|37.991||189.955|||-0.1||0.1588||-41.7964|||||1.7909|-4.0878|-3.9592|-0.3385|2|2|80.6406|115441.3667|-34.8534|1.51|1.51
adr_usa_0503|ASLN|202009|||||||||||||||-1.2284|||||||||0.6315||||||5|2.8106||9.1838||||||||||||||||||||||1.9|1.9|76.8415|69978.1|9.8266|1.84|